The state of immune system during the use of probiotic lactobacilli in complex treatment of papillomavirus infection

Cover Page


Cite item

Full Text

Abstract

Aim. Assessment of impact of probiotic lactobacilli complex on treatment efficiency and normalization of immune status in women with human papillomavirus infection (PVI).

Methods. Total of 65 patients of reproductive age with cervical pathology and PVI were examined. «Provag» was included into the standard therapy as the source of probiotic lactobacilli complex. Immunological studies were conducted before and after the treatment. The phenotypic profile of peripheral blood lymphocytes was determined by means of flow cytometry. The concentration of immunoglobulin A, G and M in serum was determined by ELISA.

Results. Decreased amounts of T- and NK-cells were observed in PVI patients on day 1. Regardless of treatment method, by day 30 the number of T-lymphocytes in the blood of women with PVI increases. Percentage of NK-cells remained below the normal values on day 30 in the group of patients who received traditional scheme of PVI treatment. Patients with PVI taking additionally probiotic lactobacilli complex showed an increase of NK-cells by the end of the treatment. On day 1 decrease of relative and absolute numbers of T-helper cells was detected. Regardless of the method of treatment by day 30 the number of T-helper cells increases to the reference level. IgM and IgG levels in peripheral blood of women with PVI were increased even on day 1. By the end of the observation period their concentration in patients with conventional treatment scheme remained increased. Patients receiving the standard therapy supplemented with «Provag» demonstrated the decrease of these classes of immunoglobulins to the reference level.

Conclusion. As a result of treatment normalization of NK-cells and T-helpers numbers was observed whereas the IgG and IgM levels remained increased.

About the authors

A G Borisov

Scientific research institute of medical issues of the North; Krasnoyarsk State Medical University named after V.F. Voino-Yasenecky

Author for correspondence.
Email: 2410454@mail.ru

A A Savchenko

Scientific research institute of medical issues of the North; Krasnoyarsk State Medical University named after V.F. Voino-Yasenecky

Email: 2410454@mail.ru

E P Tihonova

Krasnoyarsk State Medical University named after V.F. Voino-Yasenecky

Email: 2410454@mail.ru

I V Sergeeva

Krasnoyarsk State Medical University named after V.F. Voino-Yasenecky

Email: 2410454@mail.ru

E V Kasparov

Scientific research institute of medical issues of the North

Email: 2410454@mail.ru

I V Kudrjavcev

Scientific research institute of experimental medicine; Far eastern federal university

Email: 2410454@mail.ru

S S Arutjunjan

Scientific research institute of medical issues of the North

Email: 2410454@mail.ru

References

  1. Батыршина С.В., Шулаев А.В., Акберова Д.Р. Папилломавирусная инфекция: оптимизация диагностики и лечения. Клин. дерматол. и венерол. 2015; 14 (5): 67-77.
  2. Борисов А.Г., Савченко А.А., Смирнова С.В. К вопросу о классификации нарушений функционального состояния иммунной системы. Сибир. мед. ж. 2008; 23 (3): 13-18.
  3. Борисов А.Г. Клиническая характеристика нарушения функции иммунной системы. Мед. иммунол. 2013; 15 (1): 45-50.
  4. Борисов А.Г. Кластерный анализ типов иммунных нарушений при инфекционно-воспалительных заболеваниях. Рос. иммунол. ж. 2014; 8 (4): 1002-1011.
  5. Борисов А.Г., Савченко А.А., Соколовская В.К. Заболеваемость, связанная с нарушениями функции иммунной системы (на примере Красноярского края). Здравоохр. РФ. 2014; 58 (6): 38-41.
  6. Борисов А.Г., Савченко А.А., Кудрявцев И.В. Особенности иммунного реагирования при вирусных инфекциях. Инфекция и иммунитет. 2015; 5 (2): 148-156.
  7. Караулов А.В., Афанасьев С.С., Алёшкин В.А. и др. Микрофлора, колонизационная резистентность слизистых и мукозальный иммунитет. Иммунология. 2015; 36 (5): 290-295.
  8. Савченко А.А., Цуканов В.В., Родина Д.В., Борисов А.Г. Взаимосвязь иммунологических показателей и степени вирусной нагрузки при остром вирусном гепатите В. Мед. иммунол. 2011; 13 (2-3): 181-188.
  9. Хайдуков С.В., Байдун Л.А., Зурочка А.В., Тотолян А.А. Стандартизованная технология «Исследование субпопуляционного состава лимфоцитов периферической крови с применением проточных цитофлюориметров-анализаторов» (Проект). Мед. иммунол. 2012; 14 (3): 255-268.
  10. Chiappetta C., Lendaro E., Cacciotti J. et al. The 16, 18, and 45 HPV infection in high grade squamous cervical lesions in primary hr-HPV test screening program. Eur. J. Gynaecol. Oncol. 2015; 36 (6): 722-725.
  11. Dzutsev A., Goldszmid R.S., Viaud S. et al. The role of the microbiota in inflammation, carcinogenesis, and cancer therapy. Eur. J. Immunol. 2015; 45 (1): 17-31. doi: 10.1002/eji.201444972
  12. Einstein M.H., Schiller J.T., Viscidi R.P. et al. Clinician’s guide to human papillomavirus immunology: knowns and unknowns. Lancet Infect. Dis. 2009; 9 (6): 347-356. doi: 10.1016/S1473-3099(09)70108-2
  13. Gao W., Weng J., Gao Y., Chen X. Comparison of the vaginal microbiota diversity of women with and without human papillomavirus infection: a cross-sectional study. BMC Infect. Dis. 2013; 13: 271. doi: 10.1186/1471-2334-13-271
  14. Goldszmid R.S., Trinchieri G. The price of immunity. Nat. Immunol. 2012; 13: 932-938. doi: 10.1038/ni.2422
  15. Hwang L.Y., Scott M.E., Ma Y., Moscicki A.B. Higher levels of cervicovaginal inflammatory and regulatory cytokines and chemokines in healthy young women with immature cervical epithelium. J. Reprod. Immunol. 2011; 88 (1): 66-71. doi: 10.1016/j.jri.2010.07.008
  16. Jobin C. Colorectal cancer: CRC - all about microbial products and barrier function? Nat. Rev. Gastroenterol. Hepatol. 2012; 9: 694-696. doi: 10.1038/nrgastro.2012.220
  17. Lu D., Sundström K., Sparén P. et al. Bereavement is associated with an increased risk of HPV Infection and cervical cancer: An epidemiological study in Sweden. Cancer Res. 2016; 76 (3): 643-651. doi: 10.1158/0008-5472.CAN-15-1788
  18. Maecker H., McCoy P., Nussenblatt R. Standardizing immunophenotyping for the human immunology project. Nat. Rev. Immunol. 2012; 12 (6): 191-200. doi: 10.1038/nri3158
  19. Robinson C.M., Pfeiffer J.K. Viruses and the microbiota. Annu. Rev. Virol. 2014; 1: 55-69. doi: 10.1146/annurev-virology-031413-085550
  20. Sasagawa T., Takagi H., Makinoda S. Immune responses against human papillomavirus (HPV) infection and evasion of host defense in cervical cancer. J. Infect. Chemother. 2012; 18 (6): 807-815. doi: 10.1007/s10156-012-0485-5
  21. Sharma C., Khan M.A., Mohan T. et al. A synthetic chimeric peptide harboring human papillomavirus 16 cytotoxic T lymphocyte epitopes shows therapeutic potential in a murine model of cervical cancer. Immunol. Res. 2014; 58 (1): 132-138. doi: 10.1007/s12026-013-8447-2

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

© 2017 Borisov A.G., Savchenko A.A., Tihonova E.P., Sergeeva I.V., Kasparov E.V., Kudrjavcev I.V., Arutjunjan S.S.

Creative Commons License

This work is licensed
under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.




This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies